Active Ingredient(s):Oprelvekin, rh-IL-11 FDA Approved: * November 25, 1997 Pharm Company: *WYETH PHARMS INC Category:Cancer
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.
1 Chemical, pharmacological and marketing data
3 Contraindications and precautions
6 Side effects
* May have multiple approval dates, manufacturers, or labelers.